The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of treatment, recently approved therapies (GlaxoSmithKline’s Blenrep, Sanofi’s Sarclisa, Oncopeptides’ Pepaxto, and Bristol Myers Squibb / Bluebird bio’s Abecma) have expanded the number of options available. The anti-BCMA bispecific agents in addition to the CAR T-cell therapies (e.g., Janssen’s cilta-cel) are also expected to compete fiercely, along with AbbVie / Roche’s Venclexta / Venclyxto. Nevertheless, immense clinical and commercial potential exists for multiple myeloma therapies with improved efficacy, a novel mechanism of action, and/or the ability to treat underserved patient segments, such as smoldering multiple myeloma.

Questions Answered

  • What is the size of the drug-treatable multiple myeloma population, and how do the drug-treatment rates vary by geography, line of therapy, and over time?
  • How will the use of Revlimid and Velcade change over the forecast period?
  • What impact will the generic entry of these pivotal agents have on the multiple myeloma market?
  • What are thought leaders’ opinions of anti-BCMA agents that are approved or are in Phase II / III development, such as the BCMA-targeting antibody-drug conjugate Blenrep, the CAR T-cell therapies Abecma and cilta-cel, and early-phase bispecific approaches?
  • What are the drivers of, and constraints on, the multiple myeloma market? How will the entry of new antimyeloma agents shape the market?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Scope

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and country-specific surveys with 210 hematologist-oncologists treating multiple myeloma.

Epidemiology: Incidence of multiple myeloma by country, segmented by symptom.

Emerging therapies: Phase III/PR: 3 drugs; coverage of select Phase I and II products.

Table of contents

  • Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
        • November 2020
      • Q3 2020
        • September 2020
      • Q2 2020
        • June 2020
    • Key Findings
      • Multiple Myeloma - Key Findings
        • June 2020
    • Market Outlook
      • Key Findings
        • Major-Market Share of Drug Classes for Multiple Myeloma: 2019
        • Major-Market Share of Drug Classes for Multiple Myeloma: 2029
        • Major-Market Sales of Key Drugs in the Multiple Myeloma Market: 2019-2029
        • Major-Market Multiple Myeloma Sales by Line of Therapy: 2019-2029
        • Drug-Treatable Population Share and Major-Market Sales Share in Multiple Myeloma: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share in Multiple Myeloma: 2029
        • Population Positioning of Therapies in Multiple Myeloma
        • Multiple Myeloma SWOT Analysis
      • COVID-19 Areas of potential forecast impact
        • COVID-19: Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
        • Expert Insight: Impact of COVID-19 on Treatment Practices in Multiple Myeloma
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Multiple Myeloma?
        • What Factors Are Constraining the Market for Multiple Myeloma?
      • Segment-Specific Trends
        • Smoldering Multiple Myeloma
        • First-Line Transplant-Eligible Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in First-Line Transplant-Eligible Multiple Myeloma in the United States: 2019-2029
        • First-Line Transplant-Ineligible Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in First-Line Transplant-Ineligible Multiple Myeloma in the United States: 2019-2029
        • Relapsed/Refractory Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in Second-Line Multiple Myeloma in the United States: 2019-2029
        • Patient-Share Dynamics of Key Regimens in Third-Line Multiple Myeloma in the United States: 2019-2029
        • Patient-Share Dynamics of Key Regimens in Fourth-Line Multiple Myeloma in the United States: 2019-2029
        • Patient-Share Dynamics of Key Regimens in Fifth- to Seventh-Line Multiple Myeloma in the United States: 2019-2029
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Clinical Manifestations of Multiple Myeloma
      • Disease Pathophysiology
        • Overview
        • Plasma Cell and Myeloma Cell Process
      • Risk Factors
        • Select Risk Factors Associated with Multiple Myeloma
      • Staging and Classification
        • Classification of Multiple Myeloma
        • Revised IMWG Classification Criteria of Multiple Myeloma
        • Staging of Multiple Myeloma
        • Durie-Salmon Staging System for Multiple Myeloma
        • International Staging System for Multiple Myeloma
      • Key Pathways and Drug Targets
        • Drug Targets and Potential Therapies for Multiple Myeloma
        • Cell-Surface Molecules on Myeloma Cells and Bone Marrow Stromal Cells
        • IMiD-Mediated Disruption of Myeloma Cell-Microenvironment Interactions
        • The Potentially Synergistic Antitumor Effects of Proteasome and Aggresome Pathways
        • Biology of Selective Inhibitors of Nuclear Export (SINE)
        • Biology of B-Cell Maturation Antigen (BCMA)
        • Aminopeptidases in Apoptosis of Myeloma Cells
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Disease Definition
        • Methods
        • Sources Used for Diagnosed Incidence of Multiple Myeloma
        • Diagnosed Incident Cases of Multiple Myeloma: 2019-2029
        • Disease Definition
        • Methods
        • Sources Used for Symptomatic Distribution of Multiple Myeloma
        • Diagnosed Incident Cases of Multiple Myeloma by Symptoms: 2019-2029
        • Disease Definition
        • Methods
        • Sources Used for Asymptomatic Multiple Myeloma Progression to Symptomatic Multiple Myeloma
        • Asymptomatic Cases Progressing to Symptomatic Cases of Multiple Myeloma in the Major Pharmaceutical Markets: 2019-2029
        • Drug-Treatable Cases of Multiple Myeloma: 2019-2029
        • Multiple Myeloma Patient Flow
        • Drug-Treated Cases of Multiple Myeloma: 2019-2029
    • Current Treatment
      • Key Findings
        • Treatment Goals
          • Key Endpoints Used in Clinical Trials for Multiple Myeloma
        • Key Current Therapies
          • Overview
          • Mechanism of Action of Key Current Drug Classes Used for Multiple Myeloma
          • Current Treatments Used for Multiple Myeloma
          • Market Events Impacting the Use of Key Current Therapies in Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Thalomid / Thalidomide / Thaled for the Treatment of Multiple Myeloma
          • Expert Insights: Thalomid / Thalidomide / Thaled
          • Key Results from Select Clinical Trials Investigating Revlimid for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Revlimid
          • Key Ongoing Clinical Trials of Revlimid in the Treatment of Multiple Myeloma
          • Expert Insights: Revlimid
          • Key Results from Select Clinical Trials Investigating Pomalyst / Imnovid for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Pomalyst / Imnovid
          • Key Ongoing Clinical Trials Investigating Pomalyst / Imnovid in the Treatment of Multiple Myeloma
          • Expert Insights: Pomalyst / Imnovid
          • Key Results from Select Clinical Trials Investigating Velcade for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Velcade
          • Key Ongoing Clinical Trials Investigating Velcade in the Treatment of Multiple Myeloma
          • Expert Insights: Velcade
          • Key Results from Select Clinical Trials Investigating Kyprolis for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Kyprolis
          • Key Ongoing Clinical Trials of Kyprolis in the Treatment of Multiple Myeloma
          • Expert Insights: Kyprolis
          • Key Results from Select Clinical Trials Investigating Ninlaro for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Ninlaro
          • Key Ongoing Clinical Trials of Ninlaro in the Treatment of Multiple Myeloma
          • Expert Insights: Ninlaro
          • Key Results from Select Clinical Trials Investigating Farydak for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Farydak
          • Key Ongoing Clinical Trials Investigating Farydak in the Treatment of Multiple Myeloma
          • Expert Insights: Farydak
          • Key Results from Select Clinical Trials Investigating Empliciti for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Empliciti
          • Key Ongoing Clinical Trials Investigating Empliciti in the Treatment of Multiple Myeloma
          • Expert Insights: Empliciti
          • Key Results from Select Clinical Trials Investigating Darzalex for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Darzalex
          • Key Ongoing Clinical Trials of Darzalex in the Treatment of Multiple Myeloma
          • Expert Insights: Darzalex
          • Sarclisa
          • Key Results from Select Clinical Trials Investigating Sarclisa for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Sarclisa
          • Key Ongoing Clinical Trials of Sarclisa in the Treatment of Multiple Myeloma
          • Expert Insights: Sarclisa
          • Xpovio / Nexpovio
          • Key Results from Select Clinical Trials Investigating Xpovio / Nexpovio for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Xpovio / Nexpovio
          • Key Ongoing Clinical Trials of Xpovio / Nexpovio in the Treatment of Multiple Myeloma
          • Expert Insights: Xpovio / Nexpovio
          • Key Results from Select Clinical Trials Investigating Blenrep for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Blenrep
          • Key Ongoing Clinical Trials of Blenrep in the Treatment of Multiple Myeloma
          • Expert Insights: Blenrep
          • Key Results from Select Clinical Trials Investigating Abecma for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Abecma
          • Key Ongoing Clinical Trials of Abecma in the Treatment of Multiple Myeloma
          • Expert Insights: Abecma (Idecabtagene Vicleucel / Ide-Cel)
          • Key Results from Select Clinical Trials Investigating Pepaxto for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Pepaxto
          • Key Ongoing Clinical Trials of Pepaxto in the Treatment of Multiple Myeloma
          • Expert Insights: Pepaxto (melflufen)
        • Medical Practice
          • Asymptomatic Multiple Myeloma
          • First-Line Transplant-Eligible Multiple Myeloma
          • First-Line Transplant-Ineligible Multiple Myeloma
          • Relapsed/Refractory Multiple Myeloma
          • Country-Specific Multiple Myeloma Treatment Guidelines
          • Patient Characteristics Influencing Drug Selection in Multiple Myeloma
          • Treatment Decision Tree for Multiple Myeloma: United States
          • Treatment Decision Tree for Multiple Myeloma: Europe
          • Treatment Decision Tree for Multiple Myeloma: Japan
      • Unmet Need Overview
        • Attainment of Unmet Needs
          • Current and Future Attainment of Unmet Needs in Multiple Myeloma
          • Top Unmet Needs in Multiple Myeloma: Current and Future Attainment
      • Emerging Therapies
        • Key Findings
          • Pipeline Trends for Multiple Myeloma
        • Key Emerging Therapies
          • Key Therapies in Development for Multiple Myeloma
          • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Venclexta / Venclyxto for the Treatment of Multiple Myeloma
          • Key Ongoing Clinical Trials of Venclexta / Venclyxto in the Treatment of Multiple Myeloma
          • Analysis of the Clinical Development Program for Venclexta / Venclyxto
          • Expert Insights: Venclexta / Venclyxto
          • Expectations for Market Authorization and Sales Opportunity of Venclexta / Venclyxto in Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Ciltacabtagene Autoleucel for the Treatment of Multiple Myeloma
          • Key Ongoing Clinical Trials Investigating Ciltacabtagene Autoleucel in the Treatment of Multiple Myeloma
          • Analysis of the Clinical Development Program for Ciltacabtagene Autoleucel
          • Expert Insights: Ciltacabtagene Autoleucel
          • Expectations for Launch and Sales Opportunity of Ciltacabtagene Autoleucel in Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Elranatamab (PF-06863135) for the Treatment of Multiple Myeloma
          • Analysis of the Clinical Development Program for Elranatamab
          • Key Ongoing Clinical Trials Investigating Elranatamab in the Treatment of Multiple Myeloma
          • Expectations for Launch and Sales Opportunity of Elranatamab in Multiple Myeloma
        • Early-Phase Pipeline Analysis
          • Select Compounds in Early-Phase Development for Multiple Myeloma
      • Access and Reimbursement Overview
        • Region-Specific Reimbursement Practices
          • Key Market Access Considerations in Multiple Myeloma: United States
          • General Reimbursement Environment: United States
          • Key Market Access Considerations in Multiple Myeloma: EU5
          • General Reimbursement Environment: EU5
          • Key Market Access Considerations in Multiple Myeloma: Japan
          • General Reimbursement Environment: Japan
      • Appendix
        • Key Abbreviations Related to Multiple Myeloma
        • Brands, Marketers, and Generic Availability of Current Therapies Used for Multiple Myeloma by Market
        • Multiple Myeloma Bibliography

    Author(s): Snigdha Gupta, Ph.D.; Ullas Ulahannan

    Snigdha Gupta, Ph.D., is a principal analyst on the Oncology team at Clarivate. She has worked on multiple oncology indications, including non-small-cell lung cancer and multiple myeloma. She holds a Ph.D. in infectious diseases from the Indian Institute of Chemical Biology at Jadavpur University in Kolkata. She pursued a postdoctoral fellowship at the Mucosal Immunology Lab of the National Institute of Immunology in New Delhi and has been published in several peer-reviewed journals.

    Ullas Ulahannan, M.P.H., is an associate epidemiologist at Clarivate. Previously, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.


    Related Reports

    Multiple Myeloma - Epidemiology - Emerging Markets

    DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries w...

    View Details

    Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

    DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

    View Details

    Multiple Myeloma - Epidemiology - Mature Markets

    DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

    View Details

    Multiple Myeloma - Epidemiology - Americas

    DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in...

    View Details